Litigation Details for Wyeth LLC v. MSN Laboratories Private Limited (D. Del. 2017)

Wyeth LLC v. MSN Laboratories Private Limited (D. Del. 2017)

Docket	1:17-cv-00233	Date Filed	2017-03-07
Court	District Court, D. Delaware	Date Terminated	2017-09-21
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	7,767,678
Link to Docket	External link to docket

Details for Wyeth LLC v. MSN Laboratories Private Limited (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-03-07				External link to document
2017-03-06	30		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,767,678 B2. (Attachments: #… 21 September 2017 1:17-cv-00233 830 Patent None District Court, D. Delaware	External link to document
2017-03-06	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,767,678 B2;. (sar) (Entered… 21 September 2017 1:17-cv-00233 830 Patent None District Court, D. Delaware	External link to document

Wyeth LLC v. MSN Laboratories Private Limited, 1:17-cv-00233: Litigation Summary and Patent Analysis

Last updated: August 3, 2026

Wyeth LLC sued MSN Laboratories Private Limited and related entities in the U.S. District Court for the District of Delaware after MSN filed an ANDA for generic desvenlafaxine extended-release tablets, the generic equivalent of Pristiq. The case concerned Wyeth’s patent rights covering desvenlafaxine, an active metabolite of venlafaxine used to treat major depressive disorder.

The litigation was an Abbreviated New Drug Application case under the Hatch-Waxman Act. The case did not involve biosimilar competition. Public docket materials indicate that the dispute ended through a resolution and dismissal rather than a reported merits judgment establishing invalidity or noninfringement.

What drug and ANDA were at issue in Wyeth v. MSN Laboratories?

The product was desvenlafaxine succinate extended-release tablets, marketed by Wyeth and Pfizer as Pristiq.

Item	Detail
Brand drug	Pristiq
Active ingredient	Desvenlafaxine succinate
Dosage form	Extended-release oral tablet
Reference sponsor	Wyeth LLC, later associated with Pfizer
Generic applicant	MSN Laboratories Private Limited and affiliated MSN entities
Regulatory pathway	ANDA under the Hatch-Waxman Act
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:17-cv-00233
Filing year	2017
Case type	Abbreviated New Drug Application patent litigation

Desvenlafaxine is the major active metabolite of venlafaxine. Pristiq was approved by the FDA in 2008 for the treatment of major depressive disorder. The commercial dispute centered on whether MSN could obtain FDA approval and launch its generic product before expiration of Wyeth’s listed patent rights.

What patents protected Pristiq and desvenlafaxine?

The principal patent associated with Pristiq was U.S. Patent No. 6,673,838, directed to desvenlafaxine and its use in treating depression.

Patent	Subject matter	Relevance to Pristiq
U.S. Patent No. 6,673,838	Desvenlafaxine and therapeutic use	Principal Orange Book patent associated with the product
U.S. Patent No. 8,821,930	Desvenlafaxine pharmaceutical compositions and extended-release product technology	Later formulation and product protection associated with desvenlafaxine products

The '838 patent was particularly important because it covered the active pharmaceutical ingredient and therapeutic use of desvenlafaxine. Its expiration materially constrained generic launch timing.

Patent protection for Pristiq was narrower than the patent estate for many biologics or complex injectable products. The product did not depend on a large manufacturing platform or a difficult-to-reproduce delivery device. Once the core compound and formulation claims became vulnerable or expired, multiple manufacturers could enter with conventional extended-release tablets.

When did Pristiq lose patent exclusivity?

The key patent expiry date for the original desvenlafaxine protection was in 2022.

Exclusivity item	Date or status
FDA approval of Pristiq	2008
U.S. Patent No. 6,673,838 expiration	February 2022, subject to any applicable patent-term adjustments or extensions
Expected post-expiry generic competition	2022 onward
Small-molecule regulatory exclusivity	Expired before the MSN litigation concluded
Biosimilar exclusivity	Not applicable

The precise commercial launch date for an individual ANDA applicant depended on the terms of any settlement, the status of FDA approval, and remaining patent protection. A settlement could permit an applicant to launch before full expiration of every listed patent, subject to agreed conditions.

What did Wyeth allege against MSN Laboratories?

Wyeth’s complaint followed MSN’s Paragraph IV certification to listed Pristiq patents. In a Paragraph IV certification, an ANDA applicant asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

Wyeth’s claims generally involved:

1. Patent infringement under 35 U.S.C. § 271(e)(2), based on MSN’s ANDA filing.
2. A request for an order preventing FDA approval of MSN’s ANDA until expiration of the asserted patent rights.
3. A request for a statutory 30-month stay of FDA approval under the Hatch-Waxman Act.
4. Declaratory and injunctive relief concerning the proposed generic desvenlafaxine product.

MSN’s defenses in this type of litigation would have included noninfringement, invalidity under the patent statutes, and possible challenges to the scope or enforceability of the listed patents.

What was the Paragraph IV status of the case?

The case was triggered by a Paragraph IV ANDA certification. The filing of Wyeth’s complaint created the statutory 30-month stay under 21 U.S.C. § 355(j)(5)(B)(iii), unless the litigation was resolved earlier or the court ordered otherwise.

How does a Paragraph IV challenge affect generic approval?

A Paragraph IV certification allows a generic applicant to challenge brand-name patent rights before patent expiration. The generic applicant may seek approval on the position that:

• the listed patent is invalid;
• the patent is unenforceable; or
• the proposed generic product does not infringe the patent.

The first substantially complete Paragraph IV ANDA filer may also qualify for 180-day generic exclusivity under the FDA’s rules, although eligibility depends on the specific ANDA and regulatory history.

In Wyeth v. MSN, the filing did not produce a publicly reported final judgment holding the asserted patent invalid. The litigation therefore did not establish a judicial rule eliminating Wyeth’s desvenlafaxine patent rights.

What was the litigation timeline?

Date	Event
2017	Wyeth filed the Hatch-Waxman complaint in the District of Delaware
2017-2018	Pleadings, ANDA-related discovery, claim-construction and patent-validity disputes
2018-2019	Settlement-related activity and resolution of the action
After resolution	Case dismissed without a reported trial judgment determining invalidity or infringement
2022	Core patent exclusivity for Pristiq ended, permitting broader generic competition

The principal commercial value of the case was timing. The litigation was filed several years before expiry of the core desvenlafaxine patent. That period allowed Wyeth to preserve leverage over the timing and conditions of MSN’s generic entry.

What was the final litigation status?

The case ended without a publicly reported decision that invalidated U.S. Patent No. 6,673,838 or found MSN’s proposed product noninfringing. The docket reflects a negotiated resolution and dismissal.

The public record does not establish a broad judicial holding that would bind other generic applicants. The settlement therefore should be analyzed as an applicant-specific resolution rather than as a definitive test of the entire Pristiq patent estate.

Did the case produce a public settlement agreement?

A dismissal in an ANDA case commonly reflects a confidential settlement or a settlement whose commercial terms are not fully disclosed in the district-court docket. The publicly available record does not provide a complete launch-date schedule, royalty structure, supply arrangement, or license terms for MSN.

The absence of disclosed terms limits the ability to determine whether MSN received:

• an early-entry license;
• a date-certain launch right;
• a royalty-bearing license;
• a nonexclusive license shared with other generic applicants; or
• a launch right conditioned on additional patent or regulatory events.

What was the Orange Book status of Pristiq?

The Orange Book listed patent information for Pristiq and related desvenlafaxine products. The principal listed protection associated with the original product was U.S. Patent No. 6,673,838.

Orange Book issue	Analysis
Listed patent	U.S. Patent No. 6,673,838 was the key product-related patent
Use code	Associated with treatment of depression and desvenlafaxine use
Formulation protection	Later patents addressed pharmaceutical composition and extended-release technology
Generic certifications	ANDA applicants could submit Paragraph III or Paragraph IV certifications depending on the patent
Current commercial significance	Core patent expiry opened the market to multiple generic suppliers

Orange Book listings did not guarantee that every listed patent would withstand litigation. They created the statutory framework for patent certifications and the 30-month stay.

How strong was Wyeth’s patent estate?

Wyeth’s estate had moderate commercial strength but limited long-term blocking power.

Strengths

• The core patent covered desvenlafaxine, the active pharmaceutical ingredient used in Pristiq.
• The patent supported a direct infringement theory against a generic product containing the same active ingredient.
• The remaining patent term in 2017 created several years of potential launch delay.
• The brand had an established FDA-approved indication and commercial market.

Weaknesses

• The product was a conventional small-molecule oral tablet.
• Generic manufacturers could rely on ANDA bioequivalence rather than reproduce clinical development.
• Patent expiry was relatively close when the MSN case was filed.
• Later formulation patents had to be evaluated separately from the core compound and use claims.
• A settlement with one applicant would not necessarily prevent other generic applicants from challenging the same patents.

The core compound patent was stronger against a generic that used desvenlafaxine itself than a narrow formulation patent would have been. The commercial value of that protection declined rapidly as the 2022 expiry date approached.

What formulation patents protected desvenlafaxine?

Extended-release formulations created a secondary layer of protection. These patents could cover:

• release-control matrices;
• tablet composition;
• excipient combinations;
• dissolution profiles;
• dose uniformity;
• manufacturing processes; and
• pharmaceutical compositions containing desvenlafaxine succinate.

Formulation patents usually create more limited blocking positions than active-ingredient patents. A generic applicant may avoid a formulation patent by using a different excipient system, manufacturing process, or release mechanism, provided the resulting product meets FDA requirements and does not infringe the patent claims.

The presence of formulation patents therefore increased litigation complexity but did not necessarily extend practical exclusivity for the entire product market.

Did the case involve biosimilar risk?

No. Pristiq is a small-molecule drug, not a biologic. The relevant competitors were ANDA filers seeking approval for generic desvenlafaxine tablets.

The competitive risks were:

• Paragraph IV patent challenges;
• at-risk generic launch after patent litigation;
• multiple generic approvals after core patent expiry;
• price erosion from several suppliers; and
• substitution through pharmacy-level generic dispensing.

Biosimilar concepts such as interchangeability, reference-product exclusivity under the Biologics Price Competition and Innovation Act, and biosimilar patent dance procedures did not apply.

Which companies challenged Pristiq patents?

The Pristiq market attracted multiple generic applicants because the product used a chemically defined small molecule and conventional oral dosage form. Public patent litigation involving desvenlafaxine included generic applicants such as MSN and other manufacturers seeking approval for desvenlafaxine extended-release products.

The existence of parallel ANDA challenges reduced Wyeth’s ability to preserve complete market exclusivity through a single settlement. Each applicant required separate resolution, and a license to one manufacturer could increase competitive pressure from others.

What generic launch scenarios existed?

Scenario 1: Launch after core patent expiry

This was the lowest-risk scenario for generic manufacturers. Applicants could enter after expiration of the principal patent and any applicable pediatric or patent-term adjustment period.

Scenario 2: Settlement-based early entry

MSN could receive a license to launch before the final patent expiry date. The commercial terms could include a fixed launch date, a royalty, or other restrictions. The public docket does not disclose the full economic terms.

Scenario 3: At-risk launch

MSN could launch before final resolution, exposing itself to damages and injunctive relief if Wyeth prevailed. This approach was commercially possible but materially riskier in an ANDA case involving a patent covering the active ingredient.

Scenario 4: Delayed or unsuccessful ANDA approval

FDA approval could be delayed by unresolved patent certification issues, deficiencies in the ANDA, or manufacturing and regulatory review issues unrelated to the litigation.

What revenue exposure did the litigation create?

Pristiq generated meaningful revenue for Wyeth and Pfizer before broad generic entry, but the product was not protected by the type of long-term exclusivity associated with biologics or rare-disease medicines.

The revenue exposure had four components:

1. Lost sales from an earlier MSN launch.
2. Price erosion after the first generic entry.
3. Additional erosion from multiple generic suppliers.
4. Substitution away from branded Pristiq after generic availability.

The principal value of the case was the ability to delay or sequence generic entry. Once several ANDA products received FDA approval, the brand’s ability to preserve price and volume would have declined sharply.

What manufacturing and intellectual-property barriers remained?

Manufacturing barriers were limited compared with those for sterile injectables, biologics, or complex drug-device products. The main technical issues involved:

• consistent extended-release performance;
• control of tablet dissolution;
• manufacturing-scale reproducibility;
• stability of desvenlafaxine succinate;
• compliance with FDA bioequivalence requirements; and
• avoidance of formulation and process claims.

These barriers could delay approval, but they were unlikely to support durable exclusion after expiration of the compound patent.

How does Wyeth v. MSN compare with biologic patent litigation?

Issue	Pristiq and MSN litigation	Biologic litigation
Regulatory pathway	ANDA	351(k) biosimilar application
Product	Small-molecule tablet	Biologic
Main competitor	Generic manufacturer	Biosimilar sponsor
Patent process	Paragraph IV certification	BPCIA patent-exchange process
Interchangeability	Not applicable	May be relevant
Manufacturing barrier	Moderate	Often substantial
Patent estate	Compound, use, formulation	Composition, process, formulation, device, method
Price erosion	Often rapid after generic entry	Depends on biosimilar competition and interchangeability

Key Takeaways

• Wyeth v. MSN Laboratories, No. 1:17-cv-00233, was a Hatch-Waxman case involving generic desvenlafaxine extended-release tablets.
• The product was Pristiq, originally marketed by Wyeth and later associated with Pfizer.
• U.S. Patent No. 6,673,838 was the principal patent protecting desvenlafaxine and its therapeutic use.
• The case ended through negotiated resolution and dismissal rather than a reported merits judgment.
• The public record does not disclose the complete settlement terms or a definitive MSN launch date.
• Core patent protection expired in 2022, after which generic competition expanded.
• The case involved generic, not biosimilar, competition.
• Wyeth’s strongest position was the active-ingredient patent. Formulation patents provided secondary protection but were more vulnerable to design-around strategies.
• The commercial issue was timing: delaying MSN’s launch and preserving branded Pristiq revenue before broad generic entry.

FAQs About Wyeth LLC v. MSN Laboratories

Was Wyeth v. MSN Laboratories a Paragraph IV case?

Yes. The case followed MSN’s Paragraph IV certification concerning patents listed for Pristiq or desvenlafaxine products.

Did MSN invalidate Wyeth’s Pristiq patent?

No reported merits decision in the docket invalidated the principal Pristiq patent. The case was resolved and dismissed.

Did MSN receive an early-entry license for generic Pristiq?

The case was resolved through a settlement-related dismissal, but the publicly available record does not disclose complete license or launch-date terms.

Is desvenlafaxine subject to biosimilar competition?

No. Desvenlafaxine is a small-molecule drug regulated through the ANDA pathway. Its competitors are generics, not biosimilars.

What was the most important patent for Pristiq?

U.S. Patent No. 6,673,838 was the principal patent associated with desvenlafaxine and its use in treating depression. Later patents addressed formulation and product features.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
2. U.S. Patent and Trademark Office. (2004). U.S. Patent No. 6,673,838: Methods of treating depression using O-desmethylvenlafaxine. U.S. Department of Commerce.
3. U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,821,930: Pharmaceutical compositions comprising desvenlafaxine. U.S. Department of Commerce.
4. U.S. District Court for the District of Delaware. (2017). Wyeth LLC v. MSN Laboratories Private Limited, No. 1:17-cv-00233.
5. U.S. Food and Drug Administration. (2023). Approved drug products and ANDA regulatory information for desvenlafaxine extended-release tablets. FDA.